Fosun Pharma Announces its Licensed COVID-19 Vaccine Product Receives Acceptance Notice of Clinical Trial Application by NMPA
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: PR Newswire
SHANGHAI, July 14, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) announces that its subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharmaceutical Industrial") has received the acceptance notice of clinical trial application for the licensed COVID-19 vaccine product candidate BNT162b1 (the "Vaccine"). The clinical trial application of the Vaccine was accepted by the National Medical Products Administration (the "NMPA"). Dr. Aimin Hui, Senior Vice President, President of Global R&D, and Chief Medical Officer of Fosun Pharma said, "We are greatly excited about this news. Fosun Pharma's Global R&D Center has been striving for a patient-centered and clinical-driven approach to the pandemic, and actively promoting the international collaboration with BioNTech to co-develop an mRNA vaccine against the COVID-19. We hope that the clinical trial will be initiated in China as soon as possi
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- BioNTech SE (NASDAQ: BNTX) had its price target lowered by analysts at UBS Group AG from $110.00 to $101.00. They now have a "neutral" rating on the stock.MarketBeat
- This Vaccine Maker Sits on Cash Almost Equal to Its Market Value [Yahoo! Finance]Yahoo! Finance
- BioNTech gets US agency notice over default on COVID vaccine royalties [Reuters]Reuters
- UPDATE 1-BioNTech gets notice from US agency over default on COVID vaccine royalties [Yahoo! Finance]Yahoo! Finance
BNTX
Earnings
- 3/20/24 - Miss
BNTX
Sec Filings
- 3/25/24 - Form 6-K
- 3/20/24 - Form 20-F
- 3/20/24 - Form 6-K
- BNTX's page on the SEC website